Waldenstrom Macroglobulinemia clinical trials at UC Cancer
1 research study open to eligible people
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
open to eligible people ages 18 years and up
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
at UC Irvine UCSD
Last updated: